
Eli Lilly to Buy Calytrix Bio for 1.5 Billion
Eli Lilly has agreed to buy private biotech Calytrix Bio for up to 1.5 billion dollars in cash to expand its pipeline of rare blood cancer treatments. The transaction adds an early-stage antibody candidate targeting mutated calreticulin to Lillys growing hematology portfolio.
Xurve View
Insights:
Xurve View

Eli Lilly & Co agreed to acquire Calytrix Bio for up to $1.5B in cash to expand its pipeline of rare blood cancer treatments. The transaction marks the pharmaceutical giant's latest push to diversify beyond its core diabetes and weight-loss portfolio. The deal strengthens an oncology footprint that already features the FDA-approved blood cancer medicine Jaypirca.








